MENU
+Compare
SNPHF
Stock ticker: OTC
AS OF
Oct 20 closing price
Price
$10.11
Change
-$1.35 (-11.79%)
Capitalization
3.3B

SNPHF stock forecast, quote, news & analysis

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products... Show more

SNPHF
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for SNPHF with price predictions
Nov 18, 2025

SNPHF's RSI Indicator sits in oversold zone for 21 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 03, 2025. You may want to consider a long position or call options on SNPHF as a result. In of 57 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SNPHF just turned positive on November 07, 2025. Looking at past instances where SNPHF's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

SNPHF moved below its 50-day moving average on October 20, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SNPHF crossed bearishly below the 50-day moving average on October 20, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The Aroon Indicator for SNPHF entered a downward trend on November 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.839) is normal, around the industry mean (8.823). P/E Ratio (16.865) is within average values for comparable stocks, (24.048). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.059). Dividend Yield (0.025) settles around the average of (0.027) among similar stocks. P/S Ratio (1.824) is also within normal values, averaging (3.594).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SNPHF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNPHF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.

A.I.Advisor
published Dividends

SNPHF paid dividends on November 30, 2020

Santen Pharmaceutical Co., Ltd. SNPHF Stock Dividends
А dividend of $14.00 per share was paid with a record date of November 30, 2020, and an ex-dividend date of September 29, 2020. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 99.74B. The market cap for tickers in the group ranges from 72.83K to 921.91B. LLY holds the highest valuation in this group at 921.91B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -0%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 17%. CHGCF experienced the highest price growth at 17%, while SCLX experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -23%. For the same stocks of the Industry, the average monthly volume growth was 39% and the average quarterly volume growth was 590%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 32
P/E Growth Rating: 60
Price Growth Rating: 49
SMR Rating: 61
Profit Risk Rating: 74
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
SNPHF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Grand Front Osaka Tower A
Phone
+81 663217000
Employees
4073
Web
http://www.santen.co.jp